Merck KgAA news from FierceBiotech
NewsALSO NOTED: New York pumps biotech complex; Investors focus on NZ biotech; Questions about anti-TNF safety;and much more...
> The New York Times examines New York State's $43 million effort to develop a biotech hub on Long Island. Most of that money has gone into the Broad Hollow Bioscience Park on the Farmingdale Read more...
ALSO NOTED: BioSeek to collaborate with Merck KGaA; BioAlliance acquires drug rights; and much more...
> BioSeek has forged a collaboration deal with Merck KGaA to evaluate the potential of small molecules and proteins. Read more...
ALSO NOTED: U.S. hatches $265M regenerative medicine initiative; Merck KGaA budgets €1B for R&D;and much more...
> The U.S. government is creating a $265 million research initiative that will develop new stem cell technology to re-grow the skin, limbs and muscles of soldiers injured in Iraq and Afghanistan. Read more...
Avastin, Erbitux battle for lung cancer market
Genentech's stock was down this morning on results from a Phase III study of Avastin for non-small cell lung cancer. While the drug did meet the primary endpoint--an improvement in progression-free Read more...
ALSO NOTED: Ablynx pockets upfront fee; Plexxikon publishes cancer data; Solvay drug on fast track; and much more...
> Belgium's Ablynx says it has received an undisclosed milestone payment from Novartis for an exclusive license for a program involved in their alliance on therapeutic nanobodies. Read more...
Idera shares surge on Merck KGaA pact
Idera is pocketing a $40 million up front fee from Merck KGaA and hopes to make an additional $381 Read more...
Merck KGaA starts Phase III Parkinson's trial
Merck KGaA has launched a late-stage study of safinamide for Parkinson's disease. The Read more...
Big Pharma takes an interest in cancer vaccines
For two decades, biotech companies have struggled to develop therapeutic cancer vaccines designed to treat the disease by stimulating the immune system to attack cancer cells without harming normal Read more...
ALSO NOTED: Gates gives $280M to fight TB; Merck drug proves positive in Phase II;Merck KGaA exec eyes acquisitions;much more..
> Merck says that its mid-stage trial for the osteoporosis drug Odanacatib (formerly MK-0822) significantly boosted bone mineral density after 12 months. The trial tested four doses of the drug, Read more...
Erbitux clears late-stage hurdle for lung cancer
ImClone once again is feeling the tonic effects of positive trial data. Its stock price took off this morning, rising 19 percent after its European partner, Merck KGaA, reported that Erbitux helped Read more...
| Press ReleasesPRESS RELEASE: Merck Initiates a New Phase III Clinical Trial of Safinamide in Early Parkinson’s Disease Merck Initiates a New Phase III Clinical Trial of Safinamide in Early Parkinson’s Disease MOTION-Trial Will Evaluate Safety and Efficacy of Two Doses of Safinamide (50 and 100 mg once daily) as Read more... PRESS RELEASE: ImClone and BMS Announce Joint Agreement with Merck KGaA to Co-Develop and Co-Commercialize ERBITUX in Japan ImClone Systems and Bristol-Myers Squibb Announce Joint Agreement with Merck KGaA to Co-Develop and Co-Commercialize ERBITUX in Japan NEW YORK, Oct. 17 -- ImClone Systems Incorporated and Read more... PRESS RELEASE: Gene Logic Establishes Agreement with Merck Serono Gene Logic Establishes Agreement with Merck Serono to Discover New Development Paths for Multiple Clinical-Stage Drug Candidates GAITHERSBURG, Md. -- Aug 23, 2007 - Gene Logic Inc. Read more... |
Get more Merck KgAA coverage at:
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets